Results 51 to 60 of about 98,896 (358)

The IRE1α Inhibitor KIRA6 Blocks Leukotriene Biosynthesis in Human Phagocytes

open access: yesFrontiers in Pharmacology, 2022
The ER stress and Unfolded Protein Response (UPR) component inositol-requiring enzyme 1α (IRE1α) has been linked to inflammation and lipid mediator production.
Xiao Tang   +3 more
doaj   +1 more source

Conducting retrospective impact analysis to inform a medical research charity’s funding strategies: The case of Asthma UK [PDF]

open access: yes, 2013
© 2013 Hanney et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and ...
Amanda Watt   +44 more
core   +1 more source

Endogenous Ceramide 24:1 Constrains Th17‐Driven Neutrophilic Inflammation by Antagonizing EP2 Signaling

open access: yesAdvanced Science, EarlyView.
Cer24:1 levels are reduced in neutrophilic asthma and inversely correlate with disease severity and airway neutrophilia. Restoring Cer24:1 suppresses pathogenic Th17 differentiation by engaging EP2 on CD4+ T cells, thereby dampening the JAK2–STAT3–RORγt axis and reducing IL‐17 production.
Huan Liu   +11 more
wiley   +1 more source

Promising Effects of Montelukast for Critically Ill Asthma Patients via a Reduction in Delirium

open access: yesPharmaceuticals
Background: Montelukast (MTK), a potent antagonist of cysteinyl leukotriene receptor 1, has shown therapeutic promise for the treatment of neuropsychiatric disorders.
Yuan Li   +3 more
doaj   +1 more source

Phenolic acid phenethylesters and their corresponding ketones: Inhibition of 5‐lipoxygenase and stability in human blood and HepaRG cells

open access: yesPharmacology Research & Perspectives, 2019
5‐lipoxygenase (5‐LO) catalyzes the biosynthesis of leukotrienes, potent lipid mediators involved in inflammatory diseases, and both 5‐LO and the leukotrienes are validated therapeutic targets.
Maroua Mbarik   +7 more
doaj   +1 more source

Aspirin-Exacerbated Asthma

open access: yesAllergy, Asthma & Clinical Immunology, 2008
This review focuses on aspirin-exacerbated asthma (AEA). The review includes historical perspective of aspirin, prevalence, pathogenesis, clinical features and treatment of AEA.
Varghese Mathew, Lockey Richard F
doaj   +1 more source

Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo [PDF]

open access: yes, 2013
Neutrophil recruitment from blood to extravascular sites of sterile or infectious tissue damage is a hallmark of early innate immune responses, and the molecular events leading to cell exit from the bloodstream have been well defined1,2. Once outside the
Afonso, P.   +6 more
core   +2 more sources

The Emerging Parkinson's Disease Oxylipin‐Ome

open access: yesAdvanced Science, EarlyView.
ABSTRACT Parkinson Disease (PD) is increasingly considered a proteinopathy and lipidopathy. This proteinopathy+lipidopathy paradigm has been further refined to a fatty acid (FA)‐opathy, centering dysregulated FA metabolism as fundamental in PD lipid dysfunction.
Julia C. Kelliher, Saranna Fanning
wiley   +1 more source

Steroids in pediatric eosinophilic esophagitis [PDF]

open access: yes, 2014
Swallowed fluticasone and oral viscous budesonide are effective first-line therapies for eosinophilic esophagitis in children. Side effects are minimal without evidence of Cushing syndrome, as seen in treatment with systemic corticosteroids.
Contreras, Emily M., Gupta, Sandeep K.
core   +1 more source

Role of Leukotrienes and Leukotriene Modifiers in Asthma

open access: yesPharmaceuticals, 2010
Leukotrienes (LTs), including cysteinyl LTs (CysLTs) and LTB4, are potent lipid mediators that are pivotal in the pathophysiology of asthma phenotypes. At least two receptor subtypes for CysLTs – CysLT1 and CysLT2 – have been identified. Most of the pathophysiological effects of CysLTs in asthma, including increased airway smooth muscle activity ...
openaire   +3 more sources

Home - About - Disclaimer - Privacy